Immunohistochemical tumour markers in endometrial carcinoma

Endometrial adenocarcinoma is the most common malignant neoplasm of the female genital tract and, despite its relative frequency, the molecular events that contribute to the development and progression of the lesion remain poorly understood. The normal human endometrium is characterized by hormone-dependent variations during the menstrual cycle. This tightly controlled system is disturbed in endometrial hyperplasia and carcinomas and a series of changes initiate and promote progression towards the malignant phenotype. These changes can be subdivided into discrete steps, involving activation of oncogenes, inactivation of tumour suppressor genes, deregulation of cell cycle regulators or other proteins involved in tumour invasion and progression. Immunohistochemical expression of different biomarkers such as hormone receptor status (ER, PR), proliferation associated indices (PCNA, MIB1), oncogene (c-erbB-2), tumour suppressor gene products (pRb, p53 protein), cell cycle related proteins (cyclin D1, cyclin E, p21/WAF1), anti-apoptotic protein (bcl-2), adhesion molecule (CD44s), proteolytic enzyme (cathepsin D), heat shock protein (hsp27) and metallothionein (MT) has shown the contribution of these molecules to endometrial carcinogenesis in a hormone-dependent or independent manner as an early or late event. In addition, these biomarkers seem to be correlated with tumour differentiation or myometrial invasion, and therefore could be considered as indicators of the biological behaviour of endometrial carcinoma. Furthermore, the interrelationships of these molecular markers show that these genetic dysregulations could be implicated in the control of cell proliferation and differentiation, and thereby in the multistep process of endometrial carcinogenesis.

Endometrial carcinoma; lmmunohistochemical markers; Hormone receptoprs; PCNA, MIB 1; c-erbB-2; pRb; p53;

Cyclin DJ; Cyclin E; bcl-2; CD44s; Cathepsin D; hsp27; Metallothionein

[1] Bokhman J.V.: "Two pathogenetic types of endometrial carcinoma". Gynecol. Oneal., 1983, 15, 10.

[2] Sherman M.E., Bur M.E., Kurman R.J.: "p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigene­sis". Human. Pathol., 1995, 26, 1268.

[3] Sherman M.E.: "Theories of endometrial carcinogenesis: A multidisciplinary approach". Mod. Pathol., 2000, 1, 295.

[4] Li S.-F., Shiozawa, Nakayama T.K., Nikalido T., Fujii S.: "Stepwise abnormality of sex steroid hormone receptors, tumour suppressor gene products (p53 and Rb), and cycline E in uterine endometriod carcinoma". Cancer, 1996, 77, 321.

[5] Creasman W.T.: "Prognostic significance of hormone receptors in endometrial cancer". Cancer, 1993, 71, 1467.

[6] Ribarac-Stepic N., Djordjevic-Markovic R., Milasin J., Petkovic S., Matijasevic S., Sulovic V., Kanazir D.: "Steroid receptors in human uterine carcinoma. Their biological importance and therapeutic implications". Eur. J. Gynaecol. Oneal., 1985, 6, 10.

[7] Halperin R., Zehavi S., Habler L., Hadas E., Bukovsky I., Schneider D.: "Comparative immunohistochemical study of endometriod and serous papillary carcinoma of endometrium". Eur. J. Gynaecol. Oneal., 2001, 22, 122.

[8] Carcangiu M.L., Chambers J.T., Voynick I.M., Pirro M., Schwartz P.E.: "Immunohistochemical evaluation of estrogen and progesterone recep­tor content in 183 patients with endometrial carcinoma. Part I: Clinical and histologic correlations". Am. J. Clin. Pathol., 1990, 94, 247.

[9] Kleine W., Maier T., Geyer H., Pfleiderer A.: "Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance". Gynecol. Oneal., 1990, 38, 59.

[10] Ioachim E:E., Goussia A.: Kitsiou E.G., Charalabopoulos K., Mermiga E., Stefanaki S.: Retinoblastoma protein expression in normal, hyperplastic and malignant endometrium. Correlation with p53 protein expression, c-erbB-2, hormone receptors'status and proliferative activity". Dis. Markers, 2002, 18, 143.

[11] Zagorianakou N.,I oachim E.,M itselou A.,K itsou E.,Z agorianakou P.,M akrydimas G. et al.: "Immunohistochemical expression of Heat Shock Protein 27, in normal hyperplastic and malignant endometrium: Correlation with Estrogen and Progesterone Receptor Status, P53, Rb and Proliferation Associated Indices (PCNA and MIBl)". Eur. J. Gynaecol. Oneal., 2003, 24, 299.

[12] Ioffe O.B., Papadimitriou J.C., Drachenberg C.B.: "Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium". Hum. Pathol., 1998, 29, 1150.

[13] Heffner H.M., Freedman A.N., Asirwatham E., Lele S.B.: "Prognostic significance of p53, PCNA, and c-erbB-2 in endometrial adenocarcinoma". Eur. J. Gynecol. Oneal., 1999, 20, 8.

[14] Hanks S.K., Quinn A.M., Hunter T.: "The protein kinase family: of the conserved features and duced phylogeny of the catalytic domains". Science, 1988, 241, 42.

[15] Berchuck A., Rodriguez G., Kinney R.B., Soper J.T., Dodge R.K., Clarke-Pearson D.L., Bast R.C.J.: "Overexpression of her-2/neu in endometrial cancer is associated with advanced stage disease". Am. J. Obstet. Gynecol., 1991, 164, 15.

[16] Ambros R.A., Vigna P.A., Figge J., Lallakury B.V.S., Mastrangelo A., Eastamn A.Y., Malfetano J., Figge H.L., Ross J.S.: "Observations on tumour and metastatic gene status in endometrial carcinoma with particular emphasis on p53". Cancer, 1994, 73, 1686.

[17] Ito K.,S asano H.,M atsunaga G.,S ato S.,Y ajima A., Nasim S.,Garret C.T.: "Correlation between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma". J. Pathol., 1997, 183, 318.

[18] Niwa K., Murase T., Morishita S., Hashimoto M., Itoh N., Tamaya T.: "p53 overexpression and mutation in endometrial carcinoma: inverted relation with estrogen and progesterone receptor status". Cancer Detec. Prev., 1999, 23, 147.

[19] Ben-Hur H., Berman V., Sandler B., Smirnoff P, Gurevich P., Open M., Zusman I.: "Serological and immunohistochemical determinations of p5 3 protein in diagnosis of endometrial cancer: a comparative study". Eur. J. Gynaecol. Oneal., 1997, 18, 400.

[20] Shem E.B., Fintsi Y., Avinoach I., Glezerman M., Menezer J.: "p53 expression in tissue adjacent to endometrial carcinoma". Eur. J. Gynaecol. Oneal., 2002, 23, 548.

[21] Hamel N.W.,S ebo T.J.,W ilson T.O.,K eeney G.L.,R oche P.C.,S uman V.J. et al.: "Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma". Gynecol. Oneal., 1996, 62, 192.

[22] Kohler M.F., Berchuck A., Davidoff A.M., Humphrey P.A., Dodge R.K., Iglehart J.D. et al.: "Overexpression and mutation of p53 in endometrial carcinoma". Cancer Res., 1992, 52, 1622.

[23] Yamauchi N., Sakamoto A., Uozaki H., Iihara K., Machinami R.I.: "Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity". Int. J. Gynecol. Pathol., 1996, 15, 202.

[24] Strang P., Nordstrom B., Nilsson S., Bergstrom R., Tribukait B.: "Mutant p53 protein as a predictor of survival in endometrial carcinoma". Eur. J. Cancer, 1996, 32A, 598.

[25] Sung C.J., Zheng Y., Quddus M.R., Kang X., Zhang Z-F., Lauchlan S.C., Zheng W.: "p53 as a significant prognostic marker in endometrial carcinoma". Int. J. Gynecol. Cancer, 2000, 10, 119.

[26] Ayhan A., Tuncer Z.S., Ruacan S., Ayhan A., Yasui W., Tahara E.: "Abnormal expression of cripto and p53 protein in endometrial carcinoma and its precursor lesions". Eur. J. Gynaecol. Oneal., 1998, 19, 316.

[27] Johnson D., Schwarz J.K., Cress W.D., Nevins J.R.: Expression of transcription factor E2Fl induces quiescent cells to enter S phase. Nature, 1993, 365, 349.

[28] Milde- Langosch K., Riethdorf L., Bamberger A-M. and Loning T.: "P16/MTSl and pRb expression in endometrial carcinomas". Virchows Arch., 1999, 434, 23.

[29] Niemann T.H., Yilmaz A.G., McGaughy V.R., Vaccarello L.: "Retinoblastoma protein expression in endometrial hyperplasia and carcinoma". Gynecol. Oneal., 1997, 65, 232.

[30] Semczuk A., Schneider-Stock R., Miturski R., Skomra D., Tomaszewski J., Roessner A., Jakowicki J.A.: "Rb protein expression in human endometrial carcinomas-an immunohistochemical study". Pathol. Res. Pract., 2000, 196, 41.

[31] Sherr C.J.: "D-type cyclins". Trends Biochem. Sci., 1995, 20, 187.

[32] Cordon-Cardo C.: "Mutation of cell cycle regulators, Biological and clinical amplications for human neoplasia". Am. J. Pathol., 1995,147, 545.

[33] Narita F., Sato A., Hamana S., Deguchi M., Otani T., Maruo T.: "Simultaneous immunohistochemical localization of beta-catenin and cyclm Dl in differentiated but not in undifferentiated human endometrial carcinoma". Eur. J. Gynaecol. Oneal., 2003, 24, 129.

[34] Nikaido T., Li S.F., Shiozawa T., Fujii S.: "Coabnormal expressionof cyclin DI and p53 protein in human uterine endometrial carcinomas". Cancer, 1996, 78, 1248.

[35] Ito K., Sasano H., Yoshida Y., Sato S., Yajima A.: "Immunohistochemical study of cyclins D and E and cyclin dependent kinase (cdk) 2 and 4 in human endometrial carcinoma". Anticancer Res., 1998, 8, 1661.

[36] Langosch K.M., Bamberger A.M., Goemanu C., Rossing E., Rieck G., Kelp B., Loning T.: "Expression of cell cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters".1 Cancer Res. Clin. Oncol., 2001,127, 537.

[37] Session D.R., Lee G.S., Choi J., Wolgemuth D.J.: "Expression of cyclin E in gynaecologic malignancies". Gynecol. Oncol.,1999, 72, 32.

[38] Quddus M.R., Latkovich P., Castellani W.J., Sung J., Steinhoff M.M., Briggs R.C., Miranda R.N.: "Expression of cyclin DI in normal, metaplastic, hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis". Arch. Pathol. Lab.Med., 2002, 126, 459.

[30] McCluggage W.G.: "Recent advances in immunohistochemistry in gynaecological pathology". Histopathology, 2002, 40, 309.

[40] Mitselou A., Ioachim E., Zagorianakou N., Kitsiou E., Vougiouklakis T h., Agnantis N.J.: "Expression of the cell-cycle regulatory proteins (Cyclins D l and E) in endometrial carcinomas: correlations with hormone receptor status, proliferating indices, tumor suppressor genes products (p53, pRb), and clinicopathological parameters". Eur. J. Gynaecol. Oncol., 2004, 25, 719.

[41] Ito K., Sasano H., Matsunaga G., Sato S., Yajima A., Nasim S., Garret C.: "Correlations between p21 expression and clinicopathological findings, p53 gene and proteins alterations, and survival in patients with endometrial carcinoma". J. Pathol., 1997, 183, 318.

[42] Salvesen H.B., Iversen O.E., Akslen L.A.: "Prognostic significance of angiogenesis and ki-67, p53, and p21 expression: A population-based endometrial carcinoma study". J. Clin. Oncol., 1999, 17, 1382.

[43] Burton J.L., Stewart R.L., Heatley M.K., Royds J.A., Wells M.: "p53 expression, p21 expression and the apoptotic index in endometrioid endometrial adenocarcinoma". Histopathology, 1999, 35, 221.

[44] Backe J., Gassel A.M., Hauber K., Krebs S., Bartek J., Caffier H. et al.: "p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein". Int. J. Gynecol. Pathol., 1997, 16, 361.

[45] Milde-Langosch K., Bamberger A.M., Goemann C., Rossing E., Rieck G., Kelp B., Loning T.: "Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters". J. Cancer Res. Clin.Oncol., 2001, 127, 537.

[46] Ioachim E., Kitsiou E., Mitselou A., Zagorianakou N., Charalabopoulos K., Salmas M. et al.: "p2l(wafl/cipl) protein expression in normal, hyperplastic and malignant endometrium. Correlation with hormone receptor status, c-erbB-2 oncoprotein, bcl-2 and other cell cycle related proteins (Rb, p53, ki-67, PCNA)". Exp. Oncol., 2003, 25, 200.

[47] Reed J.C.: "Bcl-2 in the regulation of programmed cell death". J. Cell Biol., 1994, 124, 1.

[48] Tabibzadeh S., Zupi E., Babaknia A., Liu R., Marconi D., Romanini C.: "Site and menstrual cycle-dependent expression of proteins of the tumor necrosis factor (TNF) receptor family, and bcl-2 oncoprotein and phase-specific production of T NF-a in human endometrium". Hum. Reprod., 1995, 10, 277.

[49] Yang E., Korsmeyer S.J.: "Molecular thanatopsis: a discourse of the bcl-2 family and cell death". Blood, 1996, 88, 386.

[50] Niemann T.H., Trgovac T.L., McGaughy V.R., Vaccarello L.: "Bcl-2 expression in endometrial hyperplasia and carcinoma". Gynecol. Oncol., 1996, 63, 318.

[51] Chhieng D.C., Ross J.S., Ambros RA.: "Bcl-2 expression and the depelopment of endometrial carcinoma". Mod. Pathol., 1996, 9, 402.

[52] Henderson G.S., Brown K.A., Perkins S.L., Abbott T.M., Clayton F.: "Bcl-2 is down regulated in atypical endometrial hyperplasia and adenocarcinoma". Mod. Pathol., 1996, 9, 430.

[53] Yamauchi N., Sakamoto A., Uozaki H., Iihara K., Machinami R.: "Immunohistochemical anlysis of endometrial adenocarcinnoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity". Int. J. Gynecol. Pathol., 1996, 15, 202.

[54] Bhargava V., Kell D., van de Rijn J., Warnke R.A.: "Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor status". Am. J. Pathol., 1994, 145, 535.

[55] Mitselou A., Ioachim E., Kitsou E., Vougiouklakis T h., Zagorianakou N., Makrydimas G. et al.: "Immunohistochemical study of apoptosis related bcl-2 protein and its correlation with proliferation indices (Ki-67, PCNA), tumor suppressor genes (p53, pRb}, the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium". In vivo, 2003, 17, 469.

[56] Otsuki Y., Misaki O., Sugimoto 0., Ito Y., T sujimoto Y., Akao Y.: "Cyclic bcl-2 gene expression in human uterine endometrium during menstrual cycle". Lancet, 1994, 344, 28.

[57] Matsumura Y., Tarin D.: "Significance of CD44 gene products for cancer diagnosis and disease evaluation". Lancet, 1992, 340, 1053.

[58] Saegusa M., Machida D., Hashimura M., Okayasu I.: "CD44 expression in benign, premalignant and malignant ovarian neoplasms: Relation to tumor development and progression". J. Pathol., 1999, 189, 326.

[59] Fujita N., Yaegashi N., Ide Y., Sato S., Nakamura M., Ishiwata I., Yajima A.: "Expression of CD44 in normal human tumor endometrial tissues: possible implication of reduced expression of CD44 in lymphvascular space involvement of cancer cells". Cancer Res., 1994, 54, 3922.

[60] Katsura M., Furumoto H., Nishimura M., Kamada M., Aono T.: "Over expression of CD44 variants 6 and 7 in human endometrial cancer". Gynaecol. Oncol., 1998, 71, 185.

[61] Ayhan A., Ekrem T.C., Bildirici I., Ayhan A.: "Overexpression of CD44 variant 6 in human endometrial cancer and its prognostic significance". Gynecol. Oncol., 2001, 80, 355.

[62] Tempfer C., Haeusler G., Kaider A., Hefler L., Hanzal E., Reinthaller A. et al.: "The prognostic value of CD44 isoform expression in endometrial cancer". Brit. J. Cancer, 1998, 77, 1137.

[63] Stokes G., Shelton J., Zahn C.M., Kendall B.S.: "Association of CD44 isoform immunohistochemical expression with myometrial and vascuJar invasion in endometrioid endometrial carcinoma". Gynecol. Oncol., 2002, 84, 58.

[64] Zagorianakou N., Ioachim E., Mitselou A., Kitsiou E., Zagorianakou P., Stefanaki S. et al.: "Glycoprotein CD44s expression in normal, hyperplasic neoplastic endometrium. Immunohistochemical evaluation and correlation with p53, steroid receptor status and proliferative indices (Ki-67, PCNA)". Eur. J. Gynaecol. Oncol., 2003, 24, 500.

[65] Tokumo K., Kodama J., Seki N., Miyagi Y., Yoshinuchi M., Kudo T.: "CD44 exon v6 is not implicated in the progression and metastasis of endometrial cancer" (letter). Cancer, 1998, 125, 221.

[66] Fujita N., Sato S.: "Expression of CD44 ii n endometrial cancer and metastasis". Nippon Rinsho., 1995, 53, 1716.

[67] Yorishima T., Nagai N., Ohama K.: "Expression of CD44 alternative splicing variants in primary and lymph node metastatic lesions of gynecological cancer". Hiroshima J. Med. Sci., 1997, 46, 21.

[68] Liotta L.A.: "Tumour invasion and metastases. Role of the basement membrane". Am. J. Pathol., 1984, 117, 339.

[69] Briozzo P., Morriset M., Capony F., Rougeot C., Rochefort H.: "In vitro degradation of extracellular matrix with Mr 52.000 Cathepsin D secreted by breast cancer cells". Cancer Res., 1988, 48, 3688.

[70] Briozzo P., Badet J., Capony F., Pieri I., Montcourrier P., Barritault D., Rochefort H.: "MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D". Exp. Cell. Res., 1991, 194, 252.

[71] Westley B., Rochefort H.: "A secreted glycoprotein induced by estrogen in human breast carcinoma cell lines". Cell, 1980, 20, 353.

[72] Tandon A.K., Clark G.M., Chamness G.C., Chirgwin J.M., Mc Guire W.L.: "Cathepsin D and prognosis in breast carcinoma". N. Engl. J Med., 1990, 322, 297.

[73] Charpin C., Devictor B.. Bonnier P., Andrae L., Lavant M.N., Allacia C., Piana L.: "Cathepsin D immunocytochemical assays in breast carcinomas: image analysis and correlation lo prognostic factors". J. Pathol., 1993, 170, 463.

[74] Aaltonen M., Lipponen P., Kosma V.M., Aaltomaa S., Syrjancn K.: "Prognostic value of Cathepsin D expression in female breast carcinoma" Anticancer Res., 1995, 15, 1033.

[75] Schwartz M.K.: "Tissue cathepsins as tumour markers". Clin. Chim. Acta 1995, 237, 67.

[76] Mctaye T., Millet C., Kraimps J.L., Aubouin B., Barbier J., Begon F.: "Estrogen receptors and cathepsin D in human thyroid tissue". Carcinoma, 1993, 72, 1991.

[77] Adenis A., Huet G., Zerimech F.. Hccquet B., Balduyck M., Beyrat J.P.: "Cathepsin B. L and D activities in colorectal carcinomas: relationship with clinicopathologicaI parameters" (letter). Carcinoma, 1995, 96, 267.

[78] Maudelonde T.. Martinez P., Brouillet J.P., Laffargue F., Pages A., Rochefort H.: "Catheps in D in human endomctrium: induction by progesterone and potential value as a tumor marker". J. Clin. Endocrinol. Metah., 1990, 70, 115.

[79] Nazeer T., Malfctano J.H., Rosano T.G., Ross J.S.: "Correlation of tumor cytosol cathcpsin D with differentiation and invasiveness of endomctrial adcnocarcinoma". Am. J. Clin. Pathol., 1992, 97, 764.

[80] Kohler U., Langanke D., Sorger D., Martin R., Bilek K.: "The prognostic value of cathepsin D in endometrial carcinoma".Zentralbl Gynakol., 1995, 117, 148.

[81] Scambia G., Benedetti Panici P., Ferrandina G., Distefano M., Romanini M.E., Sica G., Mancuso S.: "Significance of cathepsin-D expression in uterine tumors". Eur. J. Cancer, 1995, 31, 1449.

[82] Nielsen A.L., Nyholm H.C.: "Endomctrial adenocarcinoma of endometrioid subtype with squamous differentiation: an immunohistochemical study of MIB-1 (Ki-67 paraffin), cathcpsin D, and c-erbB-2 protein (p l 85)". Int. J. Gynecol. Pathol., 1995, 14, 230.

[83] Gassel A.M., Backe J., Krebs S., Schon S., Caffier H., Muller-Hermelink H.K.: "Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome"..l. Clin. Pathol., 1998, 51, 25.

[84] Inoue Y., Abe K., Obata K., Doh K., Ohmura G., Hoshiai H., Noda K.: "Immunohistochcmical studies concerning cathepsin D in endomctrial carcinomas”.J. Obstet. Gynaecol. Res., 1999, 25, 345.

[85] Saygili U., Koyguncuoglu M., Altunyurt S., Guclu S., Uslu T., Ertcn O.: "May cathepsin D immunoreactivity be used as a prognostic factor in cndometrial carcinomas? A comparative immunohistochemical study". Gynecol. Oncol., 2001, 83, 20.

[86] Nazeer T., Church K., Amato C.. Ambros R.A., Rosano T.G., Malfetano J.H., Ross J.S.: "Comparative quantitative immunohistochemical and immunoradiometric determinations of cathepsin D in endometrial adenocarcinoma: predictors of tumor aggressiveness". Mod. Pathol., 1994, 7, 469.

[87] Joachim E., Kitisou E., Charalabopoulos K., Mitselou A., Zagorianakou N., Makrydimas G. et al.: "Immunohistochcmical evaluation of Cathepsin D in normal, hyperplastic and malignant endometrium. Correlation with hormone receptor status c-erbB-2, p53, Rb proteins and proliferation associated indices". Int. J. Gynecol. Cancer, 2003, 13, 344.

[88] Ciocca D.R.. Ocsterrcich S., Chamnss GC., McGuire W.L., Fuqua SA.: "Biological and clinical implications of heat shock protein 27000 (Hsp27): a review". J. Nat. Cancer institute, 1993, 85, 1558.

[89] Mahvi D.M., Carper S.W., Storm F.K.: "Over-expression of 27-kDa-heat shock protein in MCF-breast cancer cells: Effects on lymphocyte killing by natural killer and gamma delta T cells". Cancer lmmunol. lmmunother., 1993, 37, 181.

[90] Ciocca D.R., Adams D.J., Edwards D.P., Bjercke R.J. McGuire W.L.: "Distribution of an estrogen-induced protein with a molecular weight of 24,000 in normal and malignant tissues and cells". Caner Res., 1983, 31, 1204.

[91] Adams DJ., McGuire W.L.: "Quantitative enzyme-linked imrnunoassorbent assay for the estrogen related Mr 24,000 protein in human breast tumors: Correlation with estrogen and progesterone receptors". Cancer Res., 1985, 45, 2445.

[92] Devaja O., King R.J., Papadopoulos A., Raju K.S.: "Heat-shock protein 27 and its role in female reproductive organs". Eur. J. Gynaecol Oncol., 1997, 18, 16.

[93] Ciocca D.R., Puy L.A., Fasoli L.C.: "Studies of estrogen receptor, progesterone receptor, and estrogen-regulated Mr 24,000 protem in patients with carcinomas of the endometrium and cervix". Cancer Res., 1989, 4, 4298.

[94] Ciocca D.R., Stati A.O., Amprino de Castro M.M.: "Colocalization of estrogen and progesterone receptors with an estrogen regulated heat shock protein in paramn sections of human breast and endometrial cancer tissue". Breast Cancer Res. Treat., 1990, 16, 243.

[95] McGuire W.L., Dressler L.G., Sledge G.W., Ramzy I., Ciocca D.R.: "An estrogen-rcgulated protein in normal and malignant endometrium'' J. Steroid Biochem., 1986, 24, 155.

[96] Geislcr J.P., Geisler H.F., Tammela J., Miller G.A., Wiemann M.C., Zhou Z.: "A study of heat shock protein 27 in endometrial carcinoma". Gynecol. Oncol., 1999, 72, 347.

[97] Raju K.S., King R.J., Kaern J., Sumner D., Abelcr V.M., Mandalay a S., Trope C.: "Innuence of HSP27 and steroid receptor status on provera sensitivity, DNA-ploidy and survival of females with endomctrial cancer". int. J. Gynecol. Cance,; 1995, 5, 94.

[98] Wataba K., Saito T., Fukunaka K., Ashihara K., Nishimura M., Kudo R.: "Over-expression of heat shock proteins in carcinogernc endometrium". Int. J. Cancer, 2001, 91, 448.

[99] Edwards D.P., Adams DJ., Savage N., McGuire W.L.: "Estrogen induced synthesis of specific proteins in human breast cancer cells" Biochem. Biophys Res. Commun., 1980, 93, 804.

[100] Masiakowski P., Breathnach R., Bloch J.. Gannon F., Krust A., Chambon P.: "Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 Human breast cancer cell line". Nucleic Acids Res., 1982, 10, 7895.

[101] Khalid H., Tsutsumi K., Yamashita H., Kishikawa M., Yasunaga A., Shibata S.: "Expression of the small heat shock protein (hsp) 27 in human astrocytomas correlates with histologic grades and tumour growth fractions". Cell Mo/. Neurohiol., 1995, 15, 257.

[102] Malusecka E., Zborek A., Krzyzowska－Gruca S., Krawczyk Z.: "Expression of heat shock proteins HSP70 and HSP27 in primary non-small cell lung carcinomas. An immunohistochemical study". Anticancer Res., 2001, 21, 1015.

[103] Vargas-Roig L.M., Fanelli M.A., Lopez L.A., Gago E.E., Tello O., Aznar J.C., Ciocca D.R.: "Heat shock proteins and cell proliferation rn human breast cancer biopsy samples". Cancer Detect. Prev., 21, 441, 1997.

[104] Kagi J.H.R.: "Overview of metallothionein". Methods Enzymol., 1991, 205, 613.

[105] Masters B.A., Kelly E.J., Quaife C.J., Brinster R.L., Palmiter R.D.:'Targeted disruption of metallothionein I and II genes mcreases sensitivity to cadmium". Proc. Natl. Acad. Sci. USA, 1994, 91, 584.

[106] Hamer DH.: "Mctalothionein". Ann. Rev. Biochem., 1986, 55, 913.

[107] Slater E.R., Cato A.C.B.. Karin M., Baxter J.D., Beato M.: ''Progesterone induction of metallothionein-lIA gene expression". Mol Endocrinol., 1988, 2, 485.

[108] McC!uggage W.G., Maxwell P., Hamilton P.W., Jasani B.: "High metallothioncin expression is associated with featurespredictive of aggressive behaviour in cndometrial carcinoma". Histopathology, 1999, 34, SI.

[109] Ioachim E.. Kitsiou E.,C arassavoglou C.,S tefanaki S.,A gnantis N.J.: "lmmunohistochemical localization of metallothionein in endometrial lesions''. J. Pathol., 2000, 191, 269.

[110] Haerslev T.,J ackobsen K.,N edergaard L,Z edeler K.: "lmmunohistochemical detection of metallothionein in primary breastcarcinomas and their axillary lymph node metastasis". Pathol. Res. Pract., 1994, 190, 675.

[111] Schmid K.W.,E llis 1.0.,G ee J.M.W.,D arke B.M.,L ees W.E.,K ay J. et al.: "Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast". Virchows Arch. [A], 1993, 422, 153.

[112] Zeiger B.,H ittmair A.,S chir M., O fner C.,O fner D.,F ritsch P.O. et al.:''Immunohistochemically demonstrated metallothionein expression in malignant melanoma". Histopathol., 1993, 23, 257.

[113] Ohshio G.,I mamura T.,O kada N.,W ang Z.H.,Y amaki K.,K yogoku T. et al.: "Immunohistochemical study of metallothionem in pancreatic carcinomas". J. Cancer Res. Clin. Oneal., 1996, 122, 351.

[114] Joachim E.,K amina S.,D emou A., Kontostolis M.,L olis D.,A gnantis N.J.: "Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromclysin-1, CD44, extracellular matrix components, p53,Rb, c-erbB-2, EGFR, steroid receptor content and proliferation". Anticancer Res., 1999, 19, 2133.

[115] Ioachim E.,C harchanti A.,S tavropoulos N.,A thanassiou E.,M ichael M.,A gnantis N.J.: "Localization of metallothionein in urothelial carcinoma of the human urinary bladder: An immunohistochemical study including correlation with HLA-DR antigen, p53, and proliferation indices". Anticancer Res., 2001, 21, 1757.